Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Alain Wohl

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 6, 2022
Post-Ebola Symptoms 7 Years After Infection: The Natural History of Long EbolaDavid Alain Wohl, William A Fischer, Wenwen Mei, et al.
Plos Neglected Tropical Diseases|September 14, 2020
The impact of semen testing for Ebola virus RNA on sexual behavior of male Ebola survivors in LiberiaKathleen Tompkins, Jerry Brown, Sam Tozay, et al.
Contemporary Clinical Trials|March 27, 2025
Implementation of a seamless phase 2/3 study design in the setting of an emergent infectious disease pandemic: Lessons learned from the ACTIV-2 platform COVID-19 treatment trialMark J Giganti, Kara W Chew, Carlee Moser, et al.
Open Forum Infectious Diseases|April 20, 2018
Ebola Virus Ribonucleic Acid Detection in Semen More Than Two Years After Resolution of Acute Ebola Virus InfectionWilliam A Fischer, Jerry Brown, David Alain Wohl, et al.
Plos One|November 29, 2018
Stigma and Ebola survivorship in Liberia: Results from a longitudinal cohort studyLuc Overholt, David Alain Wohl, William A Fischer, et al.
The Journal of Infectious Diseases|August 31, 2023
Association Between Anterior Nasal and Plasma SARS-CoV-2 RNA Levels and Hospitalization or Death in Nonhospitalized Adults With Mild-to-Moderate COVID-19Mark J Giganti, Kara W Chew, Joseph J Eron, et al.
The Journal of Infectious Diseases|January 20, 2023
Phase 2 Safety and Antiviral Activity of SAB-185, a Novel Polyclonal Antibody Therapy for Nonhospitalized Adults With COVID-19Babafemi O Taiwo, Kara W Chew, Carlee Moser, et al.
The Journal of Infectious Diseases|July 19, 2024
Safety and Efficacy of SAB-185 for Nonhospitalized Adults With COVID-19: A Randomized Clinical TrialKara W Chew, Babafemi O Taiwo, Carlee Moser, et al.
Iscience|March 24, 2025
Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodiesRachel A Bender Ignacio, Kara W Chew, Carlee Moser, et al.
The Journal of Infectious Diseases|May 8, 2024
Characterization of Treatment Resistance and Viral Kinetics in the Setting of Single-Active Versus Dual-Active Monoclonal Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2Manish C Choudhary, Rinki Deo, Teresa H Evering, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 6, 2022
Post-Ebola Symptoms 7 Years After Infection: The Natural History of Long EbolaDavid Alain Wohl, William A Fischer, Wenwen Mei, et al.
Plos Neglected Tropical Diseases|September 14, 2020
The impact of semen testing for Ebola virus RNA on sexual behavior of male Ebola survivors in LiberiaKathleen Tompkins, Jerry Brown, Sam Tozay, et al.
Contemporary Clinical Trials|March 27, 2025
Implementation of a seamless phase 2/3 study design in the setting of an emergent infectious disease pandemic: Lessons learned from the ACTIV-2 platform COVID-19 treatment trialMark J Giganti, Kara W Chew, Carlee Moser, et al.
Open Forum Infectious Diseases|April 20, 2018
Ebola Virus Ribonucleic Acid Detection in Semen More Than Two Years After Resolution of Acute Ebola Virus InfectionWilliam A Fischer, Jerry Brown, David Alain Wohl, et al.
Plos One|November 29, 2018
Stigma and Ebola survivorship in Liberia: Results from a longitudinal cohort studyLuc Overholt, David Alain Wohl, William A Fischer, et al.
The Journal of Infectious Diseases|August 31, 2023
Association Between Anterior Nasal and Plasma SARS-CoV-2 RNA Levels and Hospitalization or Death in Nonhospitalized Adults With Mild-to-Moderate COVID-19Mark J Giganti, Kara W Chew, Joseph J Eron, et al.
The Journal of Infectious Diseases|January 20, 2023
Phase 2 Safety and Antiviral Activity of SAB-185, a Novel Polyclonal Antibody Therapy for Nonhospitalized Adults With COVID-19Babafemi O Taiwo, Kara W Chew, Carlee Moser, et al.
The Journal of Infectious Diseases|July 19, 2024
Safety and Efficacy of SAB-185 for Nonhospitalized Adults With COVID-19: A Randomized Clinical TrialKara W Chew, Babafemi O Taiwo, Carlee Moser, et al.
Iscience|March 24, 2025
Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodiesRachel A Bender Ignacio, Kara W Chew, Carlee Moser, et al.
The Journal of Infectious Diseases|May 8, 2024
Characterization of Treatment Resistance and Viral Kinetics in the Setting of Single-Active Versus Dual-Active Monoclonal Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2Manish C Choudhary, Rinki Deo, Teresa H Evering, et al.
Pageof 4